The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM)

Conclusions Inhibiting TSLP signalling with tezepelumab reduced the proportion of patients with AHR and decreased eosinophilic inflammation in BAL and airway tissue.

http://erj.ersjournals.com/cgi/content/short/59/1/2101296?rss=1

Source: European Respiratory Journal - December 31, 2021 Category: Respiratory Medicine Authors: Sverrild, A., Hansen, S., Hvidtfeldt, M., Clausson, C.-M., Cozzolino, O., Cerps, S., Uller, L., Backer, V., Erjefält, J., Porsbjerg, C. Tags: Asthma and allergy Original Articles: Asthma Source Type: research